“…Regarding the chromograninA labeling, our data as well as the data from literature revealed a striking dichotomy of synaptophysin and chromograninA expression. Synaptophysin-chromograninA co-expression was observed in 34% of our MN-NEs and in 5/92 (5%) neoplasms from the literature [ 2 – 4 , 12 , 15 , 18 , 19 , 23 , 30 , 33 , 34 , 36 , 38 – 42 , 44 , 46 , 47 , 49 , 50 , 54 ] (see Table 1 and 2 ), suggesting that the dichotomy in the synaptophysin-chromograninA expression is a common finding in these neoplasms and contrasts sharply with the expression rates in PanNETs, in which chromograninA labels 91% of the synaptophysin positive tumors [ 52 ]. Among our chromograninA, negative MN-NEs were SFT, ES, SMARCA4-deficient neoplasm, melanoma, and chordoma.…”